Indivior Shares Update On Aelis Farma's Phase 2B Study With AEF0117 In Participants With Cannabis Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Indivior announced that Aelis Farma's Phase 2B study with AEF0117 for cannabis use disorder did not meet its primary and secondary endpoints. As a result, Indivior does not expect to exercise its option on AEF0117.
September 04, 2024 | 6:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Indivior's announcement that Aelis Farma's Phase 2B study with AEF0117 did not meet endpoints may negatively impact investor sentiment. Indivior is unlikely to exercise its option on AEF0117.
The failure to meet study endpoints suggests that AEF0117 may not be a viable product for Indivior, affecting future revenue prospects. The decision not to exercise the option indicates a lack of confidence in the product's potential, likely leading to a negative short-term impact on Indivior's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90